Journal Article

Pyruvate dehydrogenase kinase/lactate axis: a therapeutic target for neovascular age-related macular degeneration identified by metabolomics

Noel, Agnès, Hubert, Pascale, Govaerts Bernadette, Hansen, Sylvain, Lecomte, Julie, de Tullio Pascal, Thys Michèle, Cavalier Etienne, Blaise, Pierre, Lambert, Vincent, Herfs, Michael, Gothot André, Schoumacher Matthieu, Yip Cassandre, Leenders Justine, Locht Bénédicte, Rakic Jean-Marie, Blacher, Silvia, Carnet Oriane, Duchateau Edouard

2020

Overview

Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in aging populations. Here, we applied metabolomics to human sera of patients with nAMD during an active (exudative) phase of the pathology and found higher lactate levels and a shift in the lipoprotein profile (increased VLDL-LDL/HDL ratio). Similar metabolomics changes were detected in the sera of mice subjected to laser-induced choroidal neovascularization (CNV). In this experimental model, we provide evidence for two sites of lactate production: first, a local one in the injured eye, and second a systemic site associated with the recruitment of bone marrow–derived inflammatory cells. Mechanistically, lactate promotes the angiogenic response and M2-like macrophage accumulation in the eyes. The therapeutic potential of our findings is demonstrated by the pharmacological control of lactate levels through pyruvate dehydrogenase kinase (PDK) inhibition by dichloroacetic acid (DCA). Mice treated with DCA exhibited normalized lactate levels and lipoprotein profiles, and inhibited CNV formation. Collectively, our findings implicate the key role of the PDK/lactate axis in AMD pathogenesis and reveal that the regulation of PDK activity has potential therapeutic value in this ocular disease. The results indicate that the lipoprotein profile is a traceable pattern that is worth considering for patient follow-up.Key messagesLactate and lipoprotein profile are associated with the active phase of AMD and CNV development.Lactate is a relevant and functional metabolite correlated with AMD progression.Modulating lactate through pyruvate dehydrogenase kinase led to a decrease of CNV progression.Pyruvate dehydrogenase kinase is a new therapeutic target for neovascular AMD.

• Publisher: Springer Nature B.V
• Subject: Aging / Angiogenesis / Blindness / Bone marrow / Dehydrogenases / Dichloroacetic acid / High density lipoprotein / Inflammation / Lactic acid / Lipoproteins / Lipoproteins (very low density) / Low density lipoprotein / Macrophages / Macular degeneration / Metabolites / Metabolomics / Pyruvic acid / Therapeutic applications / Vascularization